Organovo higher following earnings; cash balance at $49.9M

Organovo (ONVO +2.7%) ended FQ3 with $49.9M in cash/equivalents and restricted cash, down from $53.4M at the end of FQ1. The company reiterates it's on track to release a liver toxicity assay product later in 2014.

FQ3 R&D spend more than doubled Y/Y to $2.36M. SG&A spend rose 12% to $2.4M.

FQ3 results, PR

From other sites
Comments (5)
  • badeconomy
    , contributor
    Comments (251) | Send Message
    Onvo has a great management that it is going forward on the right path and delivering early and efficiently.
    7 Feb 2014, 12:39 PM Reply Like
    , contributor
    Comment (1) | Send Message
    Will this be better then 3D? kraffsblankets
    7 Feb 2014, 05:30 PM Reply Like
  • EtfcTrader
    , contributor
    Comments (33) | Send Message
    8 Feb 2014, 12:58 PM Reply Like
  • jhawkinstx
    , contributor
    Comments (78) | Send Message
    Pretty scary that a company that claims to be doing all these world changing things only has attracted 8% institutional investment.....
    10 Feb 2014, 03:22 PM Reply Like
  • riotango07
    , contributor
    Comments (69) | Send Message
    Institutions aren't always the smartest people in the room. If you want a sure thing go buy some DIS or MCD, I'm betting on the future and this is a good part of it in my portfolio. And yes, I own all the stocks I mentioned and bunch more.
    10 Feb 2014, 05:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs